Through its latest acquisition of MaSTherCell, Catalent is uniquely positioned as a full-service provider of cell and gene therapy development and manufacturing services. Catalent’s experience in autologous and allogeneic cell therapy complements its industry-leading expertise and commercial success in gene therapy development, manufacturing and adeno-associated virus (AAV) vector production. Its cell therapy offering includes expertise with a variety of cell types including chimeric antigen receptor T cells (CAR-T). With facilities in the US and Europe and continued new investments, Catalent is dedicated to supporting its customers and their patients. Catalent has produced more than 100 cGMP batches across 60+ clinical and commercial programs.
